

Resource Summary Report

Generated by [nidm-terms](#) on Aug 17, 2026

Brilliant Violet 421(TM) anti-mouse CD45

RRID:AB_10899570

Type: Antibody

Proper Citation

BioLegend Cat# 103133, RRID:AB_10899570

Antibody Information

URL: http://antibodyregistry.org/AB_10899570

Proper Citation: BioLegend Cat# 103133, RRID:AB_10899570

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, SB

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_10899570

Vendor: BioLegend

Catalog Number: 103133

Alternative Catalog Numbers: 103134

Record Creation Time: 20250819T234739+0000

Record Last Update: 20250820T062615+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD45.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Feng C, et al. (2026) METTL3/CD98-mediated glutamate efflux in CAFs drives CD8+ T cell exhaustion and impedes neoadjuvant immunochemotherapy. Cell reports, 45(2), 116933.

Pandya T, et al. (2026) Plasma signals of lung tumor promotion for molecular cancer prevention. Cell, 189(13), 3903.

Zhang Y, et al. (2026) Nociceptive neurons protect cancer cells against oxidative stress. Cell reports, 45(3), 117086.

Rispa J, et al. (2026) Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility. Cell, 189(9), 2714.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. iScience, 29(7), 116500.

Nguyen YTM, et al. (2026) Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer. Cell reports. Medicine, 102938.

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. Cancer research, 86(6), 1414.

Liao F, et al. (2026) Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. Cancer research, 86(8), 1968.

Gan L, et al. (2025) Acylglycerol Hydrolase Prevents Colitis and Colitis-Associated Colorectal Cancer by Inactivating Stimulatory LPS in the Intestine. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(8), e70566.

Li X, et al. (2025) IFN γ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. Cell death & disease, 16(1), 512.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. *Journal for immunotherapy of cancer*, 13(5).

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. *Cell reports. Medicine*, 6(3), 101975.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. *Immunity*, 58(2), 499.

Tang K, et al. (2025) Perturbation of calreticulin potentiates CD8+ T cell-mediated antitumor immunity. *The Journal of experimental medicine*, 222(10).

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. *Immunity*, 58(3), 745.

Khandibharad S, et al. (2025) Evaluating LeishPepThera (PepA) as an immuno-therapeutic for *Leishmania major* infection. *iScience*, 28(12), 114064.

Lu Y, et al. (2025) Functional Genetic Screens Reveal Key Pathways Instructing the Molecular Phenotypes of Tumor-Associated Macrophages. *Cancer immunology research*, 13(12), 2054.

Bündgen G, et al. (2025) Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. *Immunity*, 58(8), 2019.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.